- Report
- September 2025
- 250 Pages
Global
From €3994EUR$4,490USD£3,470GBP
- Report
- May 2025
- 100 Pages
Global
From €5293EUR$5,950USD£4,598GBP
- Report
- November 2024
- 100 Pages
Global
From €5293EUR$5,950USD£4,598GBP
- Report
- October 2025
- 185 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- October 2025
- 197 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- October 2025
- 187 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- October 2025
- 180 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- October 2025
- 186 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- October 2025
- 192 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- August 2025
- 188 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- August 2025
- 183 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- August 2025
- 197 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- August 2025
- 191 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- August 2025
- 180 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- August 2025
- 180 Pages
Global
From €3153EUR$3,545USD£2,740GBP
€3504EUR$3,939USD£3,044GBP
- Report
- October 2025
- 291 Pages
Global
From €5204EUR$5,850USD£4,521GBP
- Report
- September 2025
- 250 Pages
Global
From €3994EUR$4,490USD£3,470GBP
- Report
- September 2025
- 250 Pages
Global
From €3994EUR$4,490USD£3,470GBP
- Report
- September 2025
- 250 Pages
Global
From €3994EUR$4,490USD£3,470GBP
- Report
- September 2025
- 250 Pages
Global
From €3994EUR$4,490USD£3,470GBP

Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in transplant patients.
Infliximab is a biologic drug, meaning it is derived from living cells. It is produced by a number of pharmaceutical companies, including Merck, Pfizer, and Janssen. It is available in both brand-name and generic forms.
The companies in the Infliximab market include Merck, Pfizer, Janssen, Celltrion, Hospira, and Sandoz. Show Less Read more